A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

Disclosed are P. gingivalis antibodies raised against a chimeric or fusion protein, wherein the chimeric or fusion protein comprises a first peptide joined directly or through a linker to a second peptide or polypeptide, wherein (A) the first peptide comprises a region of a P. gingivalis trypsin-like enzyme and (B) the second peptide or polypeptide comprises an adhesin domain of P. gingivalis.

Anemoside B4 is used in the preparation of a medicament for the treatment of oral ulcers. For example, anemoside B4 is used in the preparation of a medicament for the treatment of recurrent oral ulcers or oral ulcers caused by chemotherapy.

Anemoside B4 is used in the preparation of a medicament for the treatment of oral ulcers. For example, anemoside B4 is used in the preparation of a medicament for the treatment of recurrent oral ulcers or oral ulcers caused by chemotherapy.

The invention relates to dentistry, and more particularly to a novel agent in the form of a gel for the treatment and/or prophylaxis of conditions characterized by loss of minerals and salts front tooth enamel. The claimed agent, provided in gel foam, for the treatment and/or prophylaxis of conditions characterized by loss of minerals and salts from tooth enamel contains the following ingredients: 19 wt % glycerin, 10 wt % xylitol 2.3 wt % hydroxyethyl cellulose, 0.09 wt % guar gum, 1 5 wt % calcium glycerophosphate, 0.12 wt % magnesium chloride, 0.9 wt % non-ionic surfactant, 0.24 wt % preservative, 0.04 wt % flavouring agent, she remainder water. The claimed agent provides effective treatment and prophylaxis of the demineralization/hypomineralization of dental tissue, mild forms of fluorosis, and the adverse consequences thereof.

A cerium oxide nanoparticle is produced by mixing a solution of an aromatic heterocyclic compound having no substituent or at least one substituent selected from the group consisting of a methyl group, an ethyl group, an amino group, an aminomethyl group, a monomethylamino group, a dimethylamino group, and a cyano group and containing 2 to 8 carbon atoms and 1 to 4 nitrogen atoms in a ring structure of the aromatic heterocyclic compound, with a solution containing a cerium (III) ion or with a cerium (III) salt, followed by addition of an oxidant.

Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.

This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with an antibacterial agent, and to methods of using and of making such compositions.

There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux esophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment.

Disclosed herein are methods of treating conditions, which may be associated with elevated levels of eosinophils and/or basophils, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.